Business
Virtual Tumour Developments Presentation at AACR
Virtual Tumour Developments Presentation at AACR.
About this update from Physiomics Plc
[{"type":"text","content":"\n \nRNS Number : 3543U Physiomics PLC 06 April 2016 \n\nPhysiomics plc\n(\"Physiomics\") or (\"the Company\")\n \nPhysiomics to give an oral presentation on new developments of the Virtual Tumour platform in drug resistance at Annual Meeting for American Association for Cancer Research (\"AACR\")\n \nPhysiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it is participating in the AACR Annual Meeting 2016, taking place at the Ernest N. Morial Convention Center, New Orleans, Louisiana on 16-20 April 2016. Dr Eric Fernandez will present on the application of the Virtual Tumour (\"VT\") platform to predict the emergence of resistance.\nDrug resistance is a major cause of treatment failure in cancer, and understanding and overcoming mechanisms of resistance is a key challenge in advancing cancer therapy. Given the significance of cancer drug resistance, and the form that future cancer therapy is likely to take, Physiomics is actively engaged in developing personalized medicine solutions. As a first step, we have incorporated chemotherapeutic resistance into our Virtual Tumour platform. This VT extension captures the fundamental mechanism by which resistance arises. Through a case study, we demonstrate that the extended VT can be applied to model the emergence of resistance in patient-derived xenografts. Furthermore, we show that the VT can be used to identify and optimize therapeutic strategies for delaying the emergence of drug resistance. Such tool could help at the patient level to improve a key clinical metric the \"time to relapse\", i.e. how long it takes for a patient to become resistant to a given treatment. \nThe abstract (\"Modeling the emergence of resistance to chemotherapeutics with virtual tumor \", No 852) will be presented in the \"Novel and Integrative Analyses of Cancer Genome Data\", Minisymposium session, scheduled 4:15 PM-6:15 PM, 17 April 2016.\n \nMore information about the conference may be found at:\nhttp://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=63&DetailItemID=363#.VvqCVMLrucx \n \nDr Christophe Chassagnole, COO of Physiomics, commented:\n\"Our enhanced Virtual Tumour capability represents the first step towards a ground-breaking tool for developing personalized treatment, which is set to revolutioniz...